These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 4498617)
21. [Muscular symptoms during fluoroquinolone treatment may be adverse effects]. Lakartidningen; 1995 Oct; 92(42):3923. PubMed ID: 7564662 [No Abstract] [Full Text] [Related]
22. [Well tolerated or risky? Adverse effect of quinolones]. Stahlmann R; Riecke K Pharm Unserer Zeit; 2001; 30(5):412-7. PubMed ID: 11575178 [No Abstract] [Full Text] [Related]
23. Adverse reactions to drugs: a comprehensive hospital inpatient survey. Smidt NA; McQueen EG N Z Med J; 1972 Dec; 76(487):397-401. PubMed ID: 4510407 [No Abstract] [Full Text] [Related]
24. Antimicrobial development and the risk-benefit assessment: recent adverse events and their implications. Tillotson GS; Blondeau JM Expert Rev Anti Infect Ther; 2006 Aug; 4(4):515-7. PubMed ID: 17009930 [No Abstract] [Full Text] [Related]
25. [Quinolones may be used in the treatment of children. Exaggerated fear of adverse effects]. Tirén U; Wennberg M; Axelsson I Lakartidningen; 1994 Sep; 91(36):3173-4. PubMed ID: 7990558 [No Abstract] [Full Text] [Related]
27. [Musculoskeletal clinical adverse effects of ofloxacin]. Martín Marco A; Falquera Sacrest M; Rubio Cabàllero M Med Clin (Barc); 1999 Nov; 113(16):635-6. PubMed ID: 10609260 [No Abstract] [Full Text] [Related]
28. Principal toxic, allergic, and other adverse effects of antimicrobial drugs. Med Lett Drugs Ther; 1971 Jun; 13(13):53-6. PubMed ID: 5162295 [No Abstract] [Full Text] [Related]
29. Antimicrobial safety and tolerability: differences and dilemmas. Mandell LA; Ball P; Tillotson G Clin Infect Dis; 2001 Mar; 32 Suppl 1():S72-9. PubMed ID: 11249832 [TBL] [Abstract][Full Text] [Related]
31. [Drug hypersensitivity in AIDS patients: report of a case]. Ribeiro LM; Pastorino AC; Grumach AS; Jacob CM Rev Hosp Clin Fac Med Sao Paulo; 1997; 52(1):23-7. PubMed ID: 9334468 [TBL] [Abstract][Full Text] [Related]
32. Epileptic myoclonus as ciprofloxacin-associated adverse effect. Striano P; Zara F; Coppola A; Ciampa C; Pezzella M; Striano S Mov Disord; 2007 Aug; 22(11):1675-6. PubMed ID: 17516482 [No Abstract] [Full Text] [Related]
35. Parenteral ciprofloxacin in persistent diarrhoea in children. Bhattacharya D J Indian Med Assoc; 1996 Feb; 94(2):74-5. PubMed ID: 8810190 [No Abstract] [Full Text] [Related]
36. Disease-modifying anti-rheumatic drugs are only one of a number of potential causes of myelosuppression: a careful drug history is necessary to elucidate the cause of an adverse event. Marshall RW; Marshall VJ; Hull R Rheumatology (Oxford); 2006 Mar; 45(3):362-3; author reply 363-4. PubMed ID: 16332952 [No Abstract] [Full Text] [Related]
37. Developing an adverse drug reaction reporting system at a teaching hospital. Baniasadi S; Fahimi F; Shalviri G Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):408-11. PubMed ID: 18312492 [TBL] [Abstract][Full Text] [Related]
38. An updated safety profile of moxifloxacin. Iannini PB; Mandell LA J Chemother; 2002 Feb; 14 Suppl 2():29-34. PubMed ID: 12003138 [No Abstract] [Full Text] [Related]
39. [Cutaneous side effects of systemic drugs. 2nd part of a synopsis. Anti-infective agents]. Zürcher K; Krebs A Dermatologica; 1973; 147():Suppl 1:1-77. PubMed ID: 4584791 [No Abstract] [Full Text] [Related]
40. Hypersensitivity reactions induced by antimicrobial drugs. Davis LE J Am Vet Med Assoc; 1984 Nov; 185(10):1131-6. PubMed ID: 6511567 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]